Stacy Lindborg

Simply because they're very sick.

They're very frail.

There's a very strong burden of cancer.

We know that 80% of women are diagnosed in late stage because you don't have distinct symptoms therefore for diagnoses to occur.

And so, but it's also one of the most exciting things.

It was a really bold move for the company when we decided frontline was the way to go.

And if I tie this back to where do I hope we'll be?

You know, right now we're studying a relatively short treatment course.

So the weekly doses that are given in phase two and now in phase three really amount to six months of treatment.

But we have women that are now well beyond five years and we still see a treatment, an overriding treatment benefit.

If you've already shown a propensity to extend life, now what if you could actually do so on a much broader scale?

timeframe, and maybe even in combinations with other treatments that ultimately have not been able to work in a cold tumor microenvironment.

We are able to convert to hot tumor microenvironment.

What things might we learn and how could that actually manifest in a way that really benefits patients?

What people will often default to.

they'll know an approach to an immunotherapy and maybe don't distinguish that there are lots of ways that we can innovate and we can actually create immunotherapy.

So they may assume that we have a viral vector or a virus that we're using to deliver our product.

They may assume that we're actually administering recombinant IL-12 or any other ways that you could bring forward a novel therapy.

And I think

You know, it's important and we intentionally designed a non-viral DNA platform.